RecruitingPhase 1NCT00595491

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge


Sponsor

Benjamin Medoff

Enrollment

313 participants

Start Date

Jan 1, 2008

Study Type

INTERVENTIONAL

Conditions

Summary

Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.


Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This pilot study is investigating the specific immune cells and chemical signals (mediators) involved in atopic dermatitis (eczema), to better understand what drives the inflammation and identify potential targets for new treatments. **You may be eligible if...** - You have been diagnosed with atopic dermatitis (eczema) - You have moderate-to-severe eczema that is not fully controlled by standard treatments - You are willing to provide skin biopsies and blood samples **You may NOT be eligible if...** - You are currently using systemic immunosuppressant medications (oral steroids or similar drugs) - You have an active skin infection in the area to be biopsied - You are pregnant or breastfeeding - You have another serious immune system disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage

Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.


Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00595491


Related Trials